• Groupe canadien de recherche en soins intensifs
    Le Groupe canadien de recherche en soins intensifs (CCCTG) est un groupe collaboratif voué à la poursuite de l’excellence et à l’avancement de la recherche en soins intensifs au Canada.
  • Groupe canadien de recherche en soins intensifs
    Plus de 30 programmes de recherche sont en cours au CCCTG et plus de 100 articles évalués par les pairs ont été publiés, toujours avec répercussions directes sur la pratique clinique en soins intensifs.
  • Groupe canadien de recherche en soins intensifs
    Le Groupe canadien de recherche en soins intensifs (CCCTG) est un organisme national de plus 300 membres intéressés à la recherche sur la prise en charge des patients gravement malades.
  • Groupe canadien de recherche en soins intensifs
    Le soutien du CCCTG indique son engagement formel à s’assurer que la recherche sera entreprise avec rigueur et éthique et communiquée en temps opportun, de manière efficace.
Membres

Nicolay Ferrari

“I am very honoured and delighted to have the opportunity to serve the Canadian Critical Care Trial Group community as the new Executive Director of the CCCTG. I look forward to building on the rich history of the group and outstanding clinical research. I am dedicated in working with the Chair, Dr. Paul Hébert, and the Executive Committee to successfully advance the strategic agenda to strengthen the key activities and support the growth of the group while maintaining the CCCTG core values of science excellence and collegiality to improve the outcomes of critically ill patients.”

Dr. Nicolay Ferrari completed his graduate studies at the Université de Montréal in 1999. He then pursued his post-doctoral work at the Dana-Farber Cancer Institute of the Harvard Medical School (Boston MA) and at the National Cancer Institute of the National Institutes of Health (Bethesda MD) developing anti-angiogenic gene therapy approaches and the use of neuronal stem cells as delivery vehicles of therapeutic genes for the treatment of brain tumors. Dr. Ferrari recently completed a Graduate Diploma in Management and Business from McGill in 2012. Following his postdoctoral studies, he spent 12 years in the biotechnology sector, first at Celmed Biosciences as Group Leader and then at Topigen Pharmaceuticals. At Topigen, as Director Pharmacology, he provided leadership for discovery and preclinical research activities that lead to the development of three novel anti-inflammatory drug candidates for the treatment of respiratory diseases, one currently in Phase 2 for the treatment of asthma. Since 2011, Dr. Ferrari is a Lecturer at the Department of Pharmacology at the Université de Sherbrooke. Just prior to joining the Canadian Critical Care Trial Group, Dr. Ferrari was the Assistant Director of the Institute of Cancer Research of the Canadian Institutes of Health Research where he assisted the development of novel funding opportunities and public-private partnerships.